2020 Virtual ESMO Review
2020 ESMO Updates in Lung Cancer: Does 1L Nivolumab–Ipilimumab Boost Unresectable Mesothelioma OS? Did the PACIFIC Trial Demonstrate Durable Benefit With Durvalumab After cCRT in Stage 3 NSCLC?
By
2020 Virtual ESMO Review
FEATURING
Martin Dietrich
By
2020 Virtual ESMO Review
FEATURING
Martin Dietrich
Comments 0
Login to view comments.
Click here to Login
